Ginkgo Bioworks to go public in SPAC deal worth over $1.6B

By The Science Advisory Board staff writers

September 15, 2021 -- Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition company (SPAC).

The deal was approved by Soaring Eagle's shareholders on September 14. Subject to customary closing conditions, Soaring Eagle anticipates that the deal with Gingko will close on September 16. Following closing, Soaring Eagle will change its name to Ginkgo Bioworks Holdings.

The combined company's shares of class A common stock and public warrants are expected to begin trading on the New York Stock Exchange on September 17, 2021, under the ticker symbols DNA and DNA.WS, respectively.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.